Opendata, web and dolomites


Laboratory Evolution of Virus-likE pRotein cAGes for Eukaryotic mRNA delivery

Total Cost €


EC-Contrib. €






 LEVERAGE mRNA project word cloud

Explore the words cloud of the LEVERAGE mRNA project. It provides you a very rough idea of what is the project "LEVERAGE mRNA" about.

acids    synthase    obtain    enter    proteinaceous    mrna    tag    encode    therapies    create    releasing    small    transport    symmetrical    messenger    engineering    disease    stimulating    artificial    electron    rna    thereby    missing    induce    capsid    initial    time    performing    microscopy    cell    lasting    pressure    inside    bacteria    thoroughly    enzyme    viruses    disassemble    cytosol    directed    replacement    enclosed    made    container    capsids    embodies    successfully    genetic    human    inhibiting    mammalian    treating    rnas    proteins    population    ribonucleic    oligonucleotides    modeling    optimize    successful    genes    nucleic    bacterial    permeant    positive    mrnas    starting    recognition    reaching    health    technologies    rational    selectively    leverage    cutting    generation    gene    nanocompartments    edge    replacing    hijacked    safely    engineer    degrade    computational    designed    variants    dysfunctional    ultimate    hollow    lumazine    organism    candidates    aals    aquifex    eukaryotic    lacking    therapy    forms    delivers    impacts    packaging    action    molecules    protein    encapsulates    sequencing    aeolicus    tolerant    evolution    containers    cells    cryo   

Project "LEVERAGE mRNA" data sheet

The following table provides information about the project.


Organization address
address: Raemistrasse 101
postcode: 8092

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 191˙149 €
 EC max contribution 191˙149 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2021-04-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

Nucleic acids are promising candidates for treating disease by stimulating, inhibiting, or replacing other nucleic acids or proteins inside of eukaryotic cells—a process known as “gene therapy.” However, methods to efficiently and safely deliver genes into cells are still lacking. The problem is that nucleic acids are not cell permeant and degrade before reaching the cytosol. One way to transport oligonucleotides into cells is by packaging them into hollow containers made of proteins, a method that has been successfully hijacked by viruses for a long time.

Here, we propose to design and engineer an artificial proteinaceous container that (1) selectively encapsulates ribonucleic acids (RNAs) using a known RNA recognition tag and (2) delivers this RNA into the cytosol of mammalian cells. Protein engineering, which embodies both rational design and computational modeling, will be used to create the starting design of this artificial protein container. The initial design will be based on the protein lumazine synthase from the bacterial organism Aquifex aeolicus (AaLS), which forms small but highly symmetrical nanocompartments in bacteria and is very tolerant to genetic changes. To optimize this design, we will use directed evolution to induce an artificial selection pressure on a large population of distinct capsid variants, allowing us to obtain only the best-performing capsid variants: those that can enter and disassemble selectively inside of mammalian cells, thereby releasing the enclosed RNA molecules into the cytosol. New AaLS containers will be thoroughly characterized using cutting-edge technologies, such next-generation sequencing and cryo-electron microscopy.

The ultimate goal of LEVERAGE mRNA is to use the designed and evolved capsids to deliver messenger RNAs (mRNAs) into cells that encode missing or dysfunctional proteins, for example in enzyme replacement therapies. If successful, this action will have lasting positive impacts on human health.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LEVERAGE MRNA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LEVERAGE MRNA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MIGPSC (2018)

Shaping the European Migration Policy: the role of the security industry

Read More  

STRESS-Mums (2019)

Study on TRansition and Exclusion in Society of Single-Mums

Read More  

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More